royal dsm capital markets day 2015 amsterdam PDF
Preview royal dsm capital markets day 2015 amsterdam
COVER SHEET ROYAL DSM CAPITAL MARKETS DAY 2015 AMSTERDAM ©2015 KENTIEDESIGN BNO BOILERPLATE — INSIDE COVER DSM – Bright Science. Brighter Living.™ Royal DSM is a global science-based company active in health, nutrition and materials. DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com. ROYAL DSM CAPITAL MARKETS DAY 4 NOVEMBER 2015 AMSTERDAM ©2015 KENTIEDESIGN BNO CONTENT SHEET Content STRATEGY 2018 1 Feike Sijbesma, CEO / Chairman of the Managing Board Driving Profitable Growth STRATEGY 2018 2 Dimitri de Vreeze, Performance Materials / Member of the Managing Board Driving Profitable Growth in Performance Materials STRATEGY 2018 3 Stephan Tanda, Nutrition / Member of the Managing Board Driving Profitable Growth in Nutrition STRATEGY 2018 4 Geraldine Matchett, CFO / Member of the Managing Board Driving Profitable Growth ROYAL DSM CAPITAL MARKETS DAY 4 NOVEMBER 2015 AMSTERDAM ©2015 KENTIEDESIGN BNO TAB 1 STRATEGY 2018 Driving Profitable Growth FEIKE SIJBESMA CEO / Chairman of the Managing Board 1 ©2015 KENTIEDESIGN BNO DSM STRATEGY 2018 Driving Profitable Growth through science-based, sustainable solutions FeFiEkIeK SEi jSbIeJBsmESaM - AC E- OC EO [D raft Version 29 (15.00 hour) - 10 -2015 ] Version 0; 21 September 2015 Presentation Geraldine Matchett, CFO [classification: secret] 4 November 2015 ROYAL DSM CAPITAL MARKETS DAY 4 NOVEMBER 2015 AMSTERDAM Safe harbor statement This presentation may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this presentation, unless required by law. A more comprehensive discussion of the risk factors affecting DSM’s business can be found in the company’s latest Annual Report, which can be found on the company's corporate website, www.dsm.com Slide 1 Agenda 1 Strategy 2010-15 − Successful transformation − Good growth platform created •2 Strategy 2018 − Improve financial results, through • Organic growth & business strategies • Cost reduction & productivity improvements • Capital efficiency • Organization and culture − Build for further future growth − Extract value from Pharma & Bulk Chemicals −3 Wrap-up Slide 2 Strategy 2010-15: Successful transformation Finalized important transformation steps − 2010-11 Base Chemicals divestments − Partnerships for Pharma in 2012 (Antibiotics) and 2014 (Contract Manufacturing) − Partnership for Bulk Chemicals in 2015 Created a high-value portfolio − Built a broad, deep and global Nutrition business − Upgraded Performance Materials businesses − Became a more global, innovative and sustainable company − Created 3 new growth platforms Slide 3 Business portfolio streamlined and simplified, creating good platform for growth Sales split – 2010 vs. 15 (€m) EBITDA split – 2010 vs. 15 (€m)1 9,000 2 1,400 8,176 2 1,161 6% 5% Sizeable Joint Ventures 2% Total sales 2015 (pro-rata) : ~€1.9bn3 9% 7,000 18% Total EBITDA 2015 (pro-rata) : ~€245m3 17% 34% 32% 1,000 23% 5,000 31% 600 3,000 63% 69% 54% Other 37% Innovation Center & Other 200 1,000 Pharma Polymer Intermediates 0 -1% 0 Performance Materials 2010 2015 2010 2015 Nutrition 1Other / Corporate Activities distributed over the Clusters pro-rata their EBITDA 2Restated, excluding Base Chemicals which was reported as Discontinued Operations 3 Includes DSM Sinochem Pharmaceuticals, DPx Patheon and ChemicaInvest (see page 40 for more detail) Slide 4 Agenda 1 Strategy 2010-15 − Successful transformation − Good growth platform created •2 Strategy 2018 − Improve financial results, through • Organic growth & business strategies • Cost reduction & productivity improvements • Capital efficiency • Organization and culture − Build for further future growth − Extract value from Pharma & Bulk Chemicals −3 Wrap-up Slide 5
Description:The list of books you might like
